The FDA approved tucatinib (Tukysa; Pfizer) in combination with trastuzumab and pertuzumab for the maintenance treatment of ...

Michael Mina, MD, PhD, explains which adverse events drove VYD2311's edge vs an mRNA COVID-19 vaccine and who may benefit most.

Sacral neuromodulation (SNM) is still considered the gold standard neuromodulation option for refractory overactive bladder ...

The FDA approved remibrutinib (Rhapsido; Novartis) today, October 7, 2026, as the first treatment for adults with symptomatic ...

Risk assessment in mantle cell lymphoma (MCL) is evolving beyond traditional clinical scores, as genomic and dynamic ...

Bilbrey’s Tennessee Oncology colleage Johnetta Blakely, MD, MS, MMHC, who is also chief medical officer for COA, has ...

Stutsky explains why shifting therapy perceptions had more pharmacist touchpoints and longer time on therapy among patients with ATTR-CM.

Lean MASLD shows milder histology than overweight and obese MASLD but similar mortality and event risk, with fibrosis tied to ...

Fibrosis stage, not MASH resolution, best predicts mortality, which should shape trial end points, says Georgetown's Zobair Younossi, MD, MPH.

Michael Mina, MD, PhD, explains which adverse events drove VYD2311's edge vs an mRNA COVID-19 vaccine and who may benefit most. Invivyd's investigational monoclonal antibody VYD2311 showed superior ...

AJMC: Despite ATTR-CM being a progressive disease, 74% of patients reported no change in perception. Is that reassuring from ...

Survivors of childhood and young adult acute lymphoblastic leukemia (ALL) treated with modern regimens had lower hip bone mineral density (BMD) than matched controls, with the largest deficits among ...